Merck’s Keytruda, Roche’s Tecentriq may lag chemo in some cancer patients, FDA says

Merck and Roche’s immunotherapies are each approved solo for certain first-line bladder cancer patients. But for other previously untreated patients, chemo may work better, the FDA warned.
Read the full story: FiercePharma: Pharma